Domain’s Resources

By targeting not only mGluR4 but also mGluR7 and 8, and by exhibiting an improved oral PK profile, DT095435 is positioned as a second generation compound that should succeed in reaching clinical efficacy where Foliglurax narrowly failed.

This poster presents bioSens-All®️, a powerful and versatile pharmacological platform which is highly adaptable for hot topic targets such as Immune Checkpoint targets (Inhibitory & Stimulatory Immune Checkpoints).

Here, we describe a novel suite of enhanced bystander bioluminescence resonance energy transfer (ebBRET)-based biosensors that were used to define the signaling profiles of 100 therapeutically relevant human GPCRs in response to endogenous (or prototypical) ligands.

We present here several innovative BRET assays dedicated to inhibitory and stimulatory ICPs (PD-1, CTLA-4, 4-1BB), and developed by us.
The ICP platform set up here shows good accuracy & robustness and represents a solid & reliable technology for ICP dedicated drug discovery.

This poster presents the last generation of our proprietary platform bioSens-All®️ which is dedicated to the identification and characterization of immune checkpoint inhibitors.

This poster presents the characterization of a proprietary NPFF receptor antagonist as a game-changer and a promising therapeutic strategy to fight the current opioid crisis.

This poster illustrates a valuable BRET-based platform used to characterize RTK candidates regarding constitutive activity, real-time kinetics or impact of RTK mutations on signalling pathways.

co-authored with Explicyte, Bordeaux, France & Institut Bergonié, Bordeaux, France, this poster discloses an in-depth GPCR expression analysis from tumor microenvironment to dissect out mechanisms of resistance to immune checkpoint inhibitors.

This poster presents the complete characterization of Domain drug candidate benchmarked to EP4 antagonist molecules currently in the clinic and demonstrating a best-in-class potential.

This poster presents the profiling of DT095435, our pan group III mGluR PAM development candidate, as a potential new anti-dyskinetic treatment for Parkinson's disease.

This study served as a validation of the utility of the Gz/G15 large-spectrum biosensor for safety and systems pharmacology profiling. Moreover, our results support the use of this cell-based functional assay in high throughput receptor deorphanization and functional screening programs.

A summary of the symposium that took place on June 4.
Chaired by IRIC's CEO Michel Bouvier, it showcases some of the latest discoveries & techniques leveraging the potential of GPCRs in oncology and immuno-oncology.